Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)

"In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~* Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~* Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~* Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles."